Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 35: 1313-1317, 1989;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kupferschmidt, R.
Right arrow Articles by Schmid, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kupferschmidt, R.
Right arrow Articles by Schmid, R. W.

Clinical Chemistry, Vol 35, 1313-1317, Copyright © 1989 by American Association for Clinical Chemistry

Specific routine determination of 3'-azido-3'-deoxythymidine (AZT) in plasma by partly automated liquid chromatography

R Kupferschmidt and RW Schmid
Laboratory of Psychoactive Drug Analysis, Psychiatric University Hospital, Vienna, Austria.

A simple isocratic HPLC method for determining azidothymidine (AZT) in serum and plasma of patients has been developed. The novel, specific, two-step, solid-phase extraction approach used for sample preparation gives a nearly quantitative recovery (95.3%) of AZT from the blood plasma matrix and requires only minimal handling of infectious clinical samples. Automatic "on-line" injection is achieved with an AASP system by switching a small cartridge, which retains the extracted analyte, into the HPLC stream. The overall HPLC procedure shows satisfying reproducibility with low standard deviation (CV: 2.1%). Because of the low detection limit (about 10 ng) and the possibility of concentrating AZT quantitatively in as much as 5 mL of plasma or serum, the method can be used in routine monitoring of AZT as well as in pharmacokinetic studies. Nevertheless, before establishing therapeutic drug monitoring for AZT, it still must be determined at what time after the last AZT dose blood specimens should be drawn for correct therapeutic interpretation of the concentration of AZT measured in blood.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
J. V. Mei, W. H. Hannon, T. L. Dobbs, C. J. Bell, C. Spruill, and M. Gwinn
Radioimmunoassay for monitoring zidovudine in dried blood spot specimens
Clin. Chem., February 1, 1998; 44(2): 281 - 286.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American Association for Clinical Chemistry.